You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. Implantable Microarray Probe for Real-Time Glutamate and GABA Detection

    SBC: ALCORIX CO            Topic: 105

    Project Summary This STTR proposal will focus on developing and testing a novel, first-on-the-market implantable biosensor for in vivo, real-time sensing of gamma-aminobutyric acid (GABA) and glutamate (GLU) for animal studies. GABA and GLU are neurotransmitters (NTs) that are essential for information processing and plasticity, memory, and other functions. GLU is the major excitatory NT and GABA ...

    STTR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  2. Combined Biomarker and EMR Data for Heterogeneous Treatment Effects and Surrogate Endpoints in Sepsis

    SBC: PRENOSIS INC            Topic: 300

    Principal Investigator/Program Director (Last, first, middle): Reddy, Jr., Bobby Project Summary: Sepsis is a poorly understood clinical syndrome characterized by dysregulated host response to infection. The complexity and heterogeneity of the host response has frustrated attempts at developing effective treatments. In partnership with 6 U.S. hospitals, Prenosis amassed NOSIS, one of the world’s ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  3. Multi-functional anti-thrombotic therapy for coronary microvascular obstruction

    SBC: APT THERAPEUTICS, INC.            Topic: NHLBI

    Principal Investigator/Program Director (Last, First, Middle: Chen, Ridong ABSTRACTAdjunctive antithrombotic treatment with dual antiplatelet therapy (aspirin + P2Y12 antagonist) plus anticoagulant (heparin or bivalirudin) is an established treatment regimen for percutaneous coronary intervention (PCI) patients. Despite aggressive antithrombotic therapy, myocardial perfusion after PCI remains inad ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  4. A Web-based Digital Health Portal for Practitioners to Improve Clinical Care and Patient Outcomes for Upper-limb Myoelectric Prosthesis Wearers

    SBC: Coapt LLC            Topic: NICHD

    7. PROJECT SUMMARY / ABSTRACT Coapt, LLC and Liberating Technologies, Inc, along with clinical collaborators at the Shirley Ryan AbilityLab, will systematically develop and evaluate a connected health system for data collected from upper limb prosthesis wearers using myoelectric control. The system will record wearer data relating to their daily prosthesis use and functional performance outside th ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  5. Point-of-care lateral flow immunoassay for diagnosis of pertussis

    SBC: DXDISCOVERY INC            Topic: NIAID

    Pertussis (Whooping cough) is a highly contagious, airborne disease that is rapidly re-emerging as a serious public health threat in the United States. Despite high vaccine coverage, annual reported cases in the U.S. have been increasing recently, with an average of 25,000 per year from 2010-2019. This is a level unseen since the early 1960s. Diagnosis of pertussis is challenging because its early ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  6. Optimization of an integrin enhancing molecule for the treatment of Duchenne muscular dystrophy

    SBC: STRYKAGEN CORPORATION            Topic: 100

    Abstract Duchenne Muscular Dystrophy (DMD) is a fatal muscle disease with an incidence of 1 in 5000 males. DMD results from mutations in the gene encoding dystrophin, a 427 kDa scaffolding protein responsible for providing a mechanical link between the muscle fiber actin cytoskeleton and laminin in the extracellular matrix. The α7β1 integrin is a transmembrane linkage system in skeletal and card ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  7. Use of Time Series Biomarker and Clinical Data to Construct a Time Trajectory Host Response Map

    SBC: PRENOSIS INC            Topic: 300

    Principal Investigator/Program Director (Last, first, middle): Reddy, Jr., Bobby Project Summary: Sepsis is an incompletely understood clinical syndrome characterized by a dysregulated host response to infection. In partnership with 8 U.S. hospitals, Prenosis amassed one of the world’s largest datasets and biobanks that combines biomarker and clinical data for patients suspected of infection, ho ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  8. GEMINI: Virtual Integrative Medical Group Visitsfor Managing Chronic Pain

    SBC: BRIGHTOUTCOME INC.            Topic: NCCIH

    Abstract Chronic pain is associated with substantial suffering and other co-morbidities such as depression, insomnia, fatigue, lowered mobility, and worse quality-of-life. Most of the care of chronic pain patients occurs during hurried primary care visits with pharmacological treatments (e.g. opioids and medications) despite mixed evidence of efficacy and increased risk of potentially dangerous si ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  9. Process Development and Preclinical Advancement of a Novel Nanoparticle Formulation for Immune Activation

    SBC: SAROS THERAPEUTICS INC            Topic: NCI

    Summary Despite the success of immune checkpoint inhibitors for some types of cancer, the overall response rate remains suboptimal. The majority of solid tumors exclude T-cells (termed “cold”), thus presenting a key limiting factor for cancer immunotherapy. Activation of the cGAS-STING pathway has been demonstrated to induce anti-tumor immune responses with impressive efficacy in preclinical s ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
  10. Optimizing NGF for Topical Treatment of Glaucoma

    SBC: HUMAN CELL CO            Topic: NEI

    ABSTRACTGlaucoma is a leading cause of irreversible vision loss, which is characterized by progressive degeneration of retinal ganglion cells (RGC) and their optic nerve axons. While age is a key risk factor, elevated intraocular pressure (IOP) is the only modifiable risk factor, with topical IOP-lowering drugs as the first line treatment. However, RGC degeneration and vision loss continues in hal ...

    SBIR Phase II 2023 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government